Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELUTIA INC.AZYO · Entity 7342 | Director · PRESIDENT AND CEO | March 08, 2022 | March 10, 2022 |
| Keenova Therapeutics plcMNK · Entity 28960 | Exec. VP & Pres, Hospital | April 02, 2018 | April 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELUTIA INC.
Report date March 08, 2022 · Filed March 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 31,775 |
Reported balance
After 2022-03-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-08 · Exercise / conversion · Acquired 4,072 · Balance 31,775 F1: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis. F2: Includes 4,552 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2032-03-08 | Direct | 138,770 |
Reported balance
After 2022-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-08 · Grant · Acquired 138,770 · Balance 138,770 F3: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 37,788 |
Reported balance
After 2022-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-08 · Grant · Acquired 37,788 · Balance 37,788 F4: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock. F5: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,216 |
Reported balance
After 2022-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-08 · Exercise / conversion · Disposed 4,072 · Balance 12,216 F1: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis. F6: On March 8, 2021, the Reporting Person was granted 16,288 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 39,894 |
Reported balance
After 2022-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-08 · Grant · Acquired 39,894 · Balance 39,894 F4: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock. F7: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.
F2: Includes 4,552 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
F3: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.
F4: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.
F5: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.
F6: On March 8, 2021, the Reporting Person was granted 16,288 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.
F7: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.
Keenova Therapeutics plc
Report date April 02, 2018 · Filed April 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 38,957 |
Reported balance
After 2018-04-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-04-02 · Grant · Acquired 21,740 · Balance 38,957 F1: Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019. F2: Includes 563 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2028-04-02 | Direct | 113,521 |
Reported balance
After 2018-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-04-02 · Grant · Acquired 113,521 · Balance 113,521 F3: The options vest in four equal annual installments beginning April 2, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019.
F2: Includes 563 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan.
F3: The options vest in four equal annual installments beginning April 2, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2022 Filed Mar 10, 2022 20:39 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantRestricted Stock Units · Derivative | 39,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002864 · form4-03102022_050359.xml · derivative · entry 5 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,894 Underlying: Class A Common Stock · 39,894 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock. F7 · derivative.exercise_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date. F7 · derivative.expiration_date: The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 20:39 UTC | ELUTIA INC. AZYO · Entity 7342 | Exercise / conversionRestricted Stock Units · Derivative | 4,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002864 · form4-03102022_050359.xml · derivative · entry 4 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,216 Underlying: Class A Common Stock · 4,072 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis. F6 · derivative.exercise_date: On March 8, 2021, the Reporting Person was granted 16,288 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022. F6 · derivative.expiration_date: On March 8, 2021, the Reporting Person was granted 16,288 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 20:39 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantRestricted Stock Units · Derivative | 37,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002864 · form4-03102022_050359.xml · derivative · entry 3 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,788 Underlying: Class A Common Stock · 37,788 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock. F5 · derivative.exercise_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024. F5 · derivative.expiration_date: The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 20:39 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 138,770 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001415889-22-002864 · form4-03102022_050359.xml · derivative · entry 2 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,770 Underlying: Class A Common Stock · 138,770 shares Expires 2032-03-08 F3 · derivative.exercise_date: The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 20:39 UTC | ELUTIA INC. AZYO · Entity 7342 | Exercise / conversionClass A Common Stock | 4,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002864 · form4-03102022_050359.xml · nonDerivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis. F2 · balance_after: Includes 4,552 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan. Read SEC document |
| May 07, 2021 Filed May 11, 2021 16:40 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 1,367 | $12.28 | $16,786.76 |
DisclosureSEC source: 0001104659-21-064573 · tm2115948-1_4seq1.xml · nonDerivative · entry 2 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,151 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.39. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2021 Filed May 11, 2021 16:40 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 7,198 | $11.65 | $83,856.70 |
DisclosureSEC source: 0001104659-21-064573 · tm2115948-1_4seq1.xml · nonDerivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,784 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.20 to $12.18. The reporting person undertakes to provide Aziyo Biologics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 16:20 UTC | ELUTIA INC. AYZO · Entity 7342 | GrantRESTRICTED STOCK UNITS · Derivative | 16,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-034467 · tm219212-5_4seq1.xml · derivative · entry 2 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,288 Underlying: CLASS A COMMON STOCK · 16,288 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 16:20 UTC | ELUTIA INC. AYZO · Entity 7342 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 97,725 | $0.00 Strike: $14.53 | $0.00 |
DisclosureSEC source: 0001104659-21-034467 · tm219212-5_4seq1.xml · derivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,725 Underlying: CLASS A COMMON STOCK · 97,725 shares Expires 2031-03-08 F1 · derivative.exercise_date: This option vests as to 25% of the shares on March 8, 2022, and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2025. Read SEC document |
| October 13, 2020 Filed Oct 13, 2020 21:57 UTC | ELUTIA INC. AZYO · Entity 7342 | ConversionSeries A Convertible Preferred Stock · Derivative | 111,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-114635 · a4.xml · derivative · entry 2 LLOYD RONALD K. · CIK 0001644078 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 14,586 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). F1 · derivative.exercise_date: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). F1 · derivative.expiration_date: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). Read SEC document |
| October 13, 2020 Filed Oct 13, 2020 21:57 UTC | ELUTIA INC. AZYO · Entity 7342 | ConversionClass A Common Stock | 14,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-114635 · a4.xml · nonDerivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 20:27 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantRestricted Stock Units · Derivative | 100,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-113579 · a4.xml · derivative · entry 2 LLOYD RONALD K. · CIK 0001644078 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,425 Underlying: Class A Common Stock · 100,425 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Class A common stock. F3 · derivative.exercise_date: The restricted stock units will vest in full on October 7, 2023 and do not have an expiration date. F3 · derivative.expiration_date: The restricted stock units will vest in full on October 7, 2023 and do not have an expiration date. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 20:27 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 181,783 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-20-113579 · a4.xml · derivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,783 Underlying: Class A Common Stock · 181,783 shares Expires 2030-10-06 F1 · derivative.exercise_date: This option vests and becomes exercisable in 4 substantially equal annual installments on each of the successive years following October 7, 2020. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:08 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 113,521 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0000950138-18-000311 · edgar.xml · derivative · entry 2 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,521 Underlying: Ordinary Shares · 113,521 shares Expires 2028-04-02 F3 · derivative.exercise_date: The options vest in four equal annual installments beginning April 2, 2019. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:08 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 21,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000311 · edgar.xml · nonDerivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,957 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019. F2 · balance_after: Includes 563 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 04, 2018 Filed Jan 6, 2018 00:30 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 299 | $23.40 | $6,996.60 |
DisclosureSEC source: 0000950138-18-000045 · edgar.xml · nonDerivative · entry 3 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,654 Read SEC document |
| January 03, 2018 Filed Jan 6, 2018 00:30 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,068 | $23.51 | $25,108.68 |
DisclosureSEC source: 0000950138-18-000045 · edgar.xml · nonDerivative · entry 2 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,953 Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:19 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 5,000 | $41.26 | $206,320.00 |
DisclosureSEC source: 0000950138-17-000478 · edgar.xml · nonDerivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,967 F1 · balance_after: Includes 324 shares acquired between December 31, 2016 and March 31, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 04, 2017 Filed Jan 6, 2018 00:30 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 293 | $53.19 | $15,584.67 |
DisclosureSEC source: 0000950138-18-000045 · edgar.xml · nonDerivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,021 F1 · balance_after: Includes 347 shares acquired between June 30, 2017 and December 31, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 33,260 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000950138-17-000020 · edgar.xml · derivative · entry 4 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,260 Underlying: Ordinary Shares · 33,260 shares Expires 2027-01-03 F5 · derivative.exercise_date: The options vest in their entirety on January 3, 2021. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 47,525 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000950138-17-000020 · edgar.xml · derivative · entry 3 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,525 Underlying: Ordinary Shares · 47,525 shares Expires 2027-01-03 F4 · derivative.exercise_date: The options vest in four equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000020 · edgar.xml · nonDerivative · entry 2 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,643 F3 · shares: Represents restricted stock units that vest in three equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 8,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000020 · edgar.xml · nonDerivative · entry 1 LLOYD RONALD K. · CIK 0001644078 · Exec. VP & Pres, Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,518 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018. F2 · balance_after: Includes 303 shares acquired between April 6, 2016 and September 30, 2016 under the Mallinckrodt employee stock purchase plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.